Comparing Sera Prognostics (NASDAQ:SERA) and Intelligent Bio Solutions (NASDAQ:INBS)

Sera Prognostics (NASDAQ:SERA) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Risk & Volatility

Sera Prognostics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.24, suggesting that its stock price is 324% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Sera Prognostics and Intelligent Bio Solutions, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1	0	0	1	2.50
Intelligent Bio Solutions	1	0	0	0	1.00

Sera Prognostics presently has a consensus target price of $5.00, suggesting a potential upside of 214.47%. Given Sera Prognostics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Sera Prognostics is more favorable than Intelligent Bio Solutions.

Profitability

This table compares Sera Prognostics and Intelligent Bio Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
Intelligent Bio Solutions	-315.33%	-200.68%	-97.31%

Insider and Institutional Ownership

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by company insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Sera Prognostics and Intelligent Bio Solutions”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80,000.00	777.91	-$31.93 million	($0.65)	-2.45
Intelligent Bio Solutions	$3.05 million	2.62	-$10.57 million	($14.82)	-0.27

Intelligent Bio Solutions has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

Sera Prognostics beats Intelligent Bio Solutions on 9 of the 14 factors compared between the two stocks.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.